testosterone and female human sexuality
- From: James Michael Howard <jmhoward@xxxxxxxxxxxxxxxx>
- Date: Fri, 02 Jun 2006 10:17:07 GMT
Menopause. 2006 May 25; [Epub ahead of print]
Efficacy and safety of a testosterone patch for the treatment of hypoactive
sexual desire disorder in surgically menopausal women: a randomized,
placebo-controlled trial.
Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot J, Rees M,
Moufarege A, Rodenberg C, Buch A, Purdie DW.
From 1The Jean Hailes Foundation, Clayton, Australia, and the Department ofMedicine, CECS, Monash University, Prahran, Victoria, Australia;
2Department of Obstetrics and Gynaecology, VU University Medical Centre,
Amsterdam, The Netherlands; 3Department of Sexology & Psychosomatic
Obstetrics/Gynaecology, Academic Medical Centre, University of Amsterdam,
The Netherlands; 4Hopital Mere et Enfants, Service de Gynecologie
Obstetrique, Nantes Cedex, France; 5Endocrinology Department, CHU Rangueil,
Toulouse, France; 6John Radcliffe Hospital, Women's Centre, Headington,
Oxford, UK; 7Procter & Gamble Pharmaceuticals, Egham, Surrey, UK; 8Procter
& Gamble Pharmaceuticals, Health Care Research Center, Mason, OH; and
10Edinburgh Osteoporosis Centre, Edinburgh, Scotland.
OBJECTIVE:: Evaluation of the use of testosterone therapy for hypoactive
sexual desire disorder (HSDD) after oophorectomy has mostly involved women
treated with oral estrogen preparations. We investigated the efficacy and
safety of a testosterone patch in surgically menopausal women receiving
concurrent transdermal estrogen. DESIGN:: Women with HSDD after
oophorectomy, for whom this was a concern, who were using transdermal
estrogen, were recruited to a 24-week, randomized, double-blind,
placebo-controlled trial in Europe and Australia. Patients were randomly
allocated to placebo (n = 40) or testosterone 300 mug/day (n = 37)
treatment. Primary endpoints were changes in sexual desire measured by the
sexual desire domain of the Profile of Female Sexual Function and the
frequency of satisfying sexual activity at 24 weeks. RESULTS:: Sixty-one
women (79%) completed the trial. All subjects who received at least one
application of study medication were included in analysis. The
testosterone-treated group experienced a significantly greater change from
baseline in the domain sexual desire score compared with placebo (change
from baseline, 16.43 versus 5.98; P = 0.02). The domain scores for arousal,
orgasm, decreased sexual concerns, responsiveness, and self-image as well
as decreased distress were also significantly greater with testosterone
therapy than placebo. The frequency of satisfactory sexual events increased
but was not statistically different between treatment groups (P = 0.06)
Adverse events occurred with similar frequency in both groups, and no
serious risks of therapy were observed CONCLUSIONS:: In this study,
transdermal testosterone therapy via a skin patch improved sexual desire
and other sexual function domains. It was well tolerated in these
oophorectomized women with HSDD receiving concomitant transdermal estrogen.
.
- Prev by Date: If one has plenty of DHEA, one has plenty of androstenediol
- Next by Date: Re: If one has plenty of DHEA, one has plenty of androstenediol
- Previous by thread: If one has plenty of DHEA, one has plenty of androstenediol
- Next by thread: Re: To the real anthropologists (you know who you are)
- Index(es):
Relevant Pages
|
